Inhibrx Biosciences, Inc. INBX Proceeds from secured term loan
Proceeds from secured term loan at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSecuredDebt.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s proceeds from secured term loan.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s proceeds from secured term loan?
- Inhibrx Biosciences, Inc. (INBX) reported proceeds from secured term loan of $74.99M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s proceeds from secured term loan changed year-over-year?
- Inhibrx Biosciences, Inc.'s proceeds from secured term loan decreased by 25.0% year-over-year, from $99.97M to $74.99M.
- What does proceeds from secured term loan mean?
- This represents the total cash inflows received from borrowing activities where specific company assets are pledged as collateral. It serves as a primary indicator of the company's ability to access debt capital markets to fund operations or research and development. A significant reliance on secured debt may reflect the company's credit risk profile and its strategy for managing capital structure.